Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season

Ainara Mira-Iglesias, F. Xavier López-Labrador, Javier García-Rubio, Beatriz Mengual-Chuliá, Miguel Tortajada-Girbés, Joan Mollar-Maseres, Mario Carballido-Fernández, Germán Schwarz-Chavarri, Joan Puig-Barberà and Javier Díez-Domingo
Additional contact information
Ainara Mira-Iglesias: Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain
F. Xavier López-Labrador: Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain
Javier García-Rubio: Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain
Beatriz Mengual-Chuliá: Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain
Miguel Tortajada-Girbés: Hospital Universitario Doctor Peset, 46017 Valencia, Spain
Joan Mollar-Maseres: Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain
Mario Carballido-Fernández: Hospital General Universitario de Castellón, 12004 Castellón, Spain
Germán Schwarz-Chavarri: Hospital General Universitario de Alicante, 03010 Alicante, Spain
Joan Puig-Barberà: Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain
Javier Díez-Domingo: Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain

IJERPH, 2021, vol. 18, issue 3, 1-19

Abstract: Influenza vaccination is annually recommended for specific populations at risk, such as older adults. We estimated the 2018/2019 influenza vaccine effectiveness (IVE) overall, by influenza subtype, type of vaccine, and by time elapsed since vaccination among subjects 65 years old or over in a multicenter prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Information about potential confounders was obtained from clinical registries and/or by interviewing patients and vaccination details were only ascertained by registries. A test-negative design was performed in order to estimate IVE. As a result, IVE was estimated at 46% (95% confidence interval (CI): (16%, 66%)), 41% (95% CI: (?34%, 74%)), and 45% (95% CI: (7%, 67%)) against overall influenza, A(H1N1)pdm09 and A(H3N2), respectively. An intra-seasonal not relevant waning effect was detected. The IVE for the adjuvanted vaccine in ?75 years old was 45% (2%, 69%) and for the non-adjuvanted vaccine in 65–74 years old was 59% (?16%, 86%). Thus, our data revealed moderate vaccine effectiveness against influenza A(H3N2) and not significant against A(H1N1)pdm09. Significant protection was conferred by the adjuvanted vaccine to patients ?75 years old. Moreover, an intra-seasonal not relevant waning effect was detected, and a not significant IVE decreasing trend was observed over time.

Keywords: influenza; vaccine; effectiveness; hospitalizations; waning; surveillance (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/3/1129/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/3/1129/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:3:p:1129-:d:488251

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().